<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Physiol Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Physiol. Rev</journal-id>
<journal-id journal-id-type="hwp">physrev</journal-id>
<journal-id journal-id-type="pmc">physrev</journal-id>
<journal-id journal-id-type="publisher-id">PHYSREV</journal-id>
<journal-title-group>
<journal-title>Physiological Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-9333</issn>
<issn pub-type="epub">1522-1210</issn>
<publisher>
<publisher-name>American Physiological Society</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28298428</article-id>
<article-id pub-id-type="pmc">5539405</article-id>
<article-id pub-id-type="publisher-id">PRV-00010-2016</article-id>
<article-id pub-id-type="doi">10.1152/physrev.00010.2016</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-5856-2813</contrib-id>
<name>
<surname>Dalmau</surname>
<given-names>Josep</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geis</surname>
<given-names>Christian</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graus</surname>
<given-names>Francesc</given-names>
</name>
</contrib>
<aff>Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Hans-Berger Department of Neurology, Jena University Hospital, Jena, Germany; Servei de Neurologia, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain</aff>
</contrib-group>
<pub-date pub-type="epub">
<day>15</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>4</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>97</volume>
<issue>2</issue>
<fpage>839</fpage>
<lpage>887</lpage>
<permissions>
<copyright-statement>Copyright © 2017 the American Physiological Society</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Physiological Society</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="z9j00217000839.pdf"></self-uri>
<self-uri xlink:href="z9j00217280100g1.gif" xlink:role="icon"></self-uri>
<abstract>
<p>Investigations in the last 10 years have revealed a new category of neurological diseases mediated by antibodies against cell surface and synaptic proteins. There are currently 16 such diseases all characterized by autoantibodies against neuronal proteins involved in synaptic signaling and plasticity. In clinical practice these findings have changed the diagnostic and treatment approach to potentially lethal, but now treatable, neurological and psychiatric syndromes previously considered idiopathic or not even suspected to be immune-mediated. Studies show that patients' antibodies can impair the surface dynamics of the target receptors eliminating them from synapses (e.g., NMDA receptor), block the function of the antigens without changing their synaptic density (e.g., GABAb receptor), interfere with synaptic protein-protein interactions (LGI1, Caspr2), alter synapse formation (e.g., neurexin-3α), or by unclear mechanisms associate to a new form of tauopathy (IgLON5). Here we first trace the process of discovery of these diseases, describing the triggers and symptoms related to each autoantigen, and then review in detail the structural and functional alterations caused by the autoantibodies with special emphasis in those (NMDA receptor, amphiphysin) that have been modeled in animals.</p>
</abstract>
<funding-group>
<award-group id="award1">
<funding-source><named-content content-type="funder-id">http://doi.org/10.13039/100000065</named-content>
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</funding-source>
<award-id>RO1NS077851</award-id>
</award-group>
<award-group id="award2">
<funding-source><named-content content-type="funder-id">http://doi.org/10.13039/501100004587</named-content>
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Carlos III Health Institute)</funding-source>
<award-id>14/00203</award-id>
<award-id>CIBERER</award-id>
<award-id>15/00377</award-id>
</award-group>
<award-group id="award3">
<funding-source>Fundacio CELLEX</funding-source>
</award-group>
<award-group id="award4">
<funding-source><named-content content-type="funder-id">http://doi.org/10.13039/501100003108</named-content>
Federal Ministry of Health, Germany | Bundeszentrale für gesundheitliche Aufklärung (Federal Centre for Health Education)</funding-source>
<award-id>GE 2519/3-1</award-id>
<award-id>CRC-TR 166/1 B2</award-id>
</award-group>
<award-group id="award5">
<funding-source>Fundacio la Marato TV3</funding-source>
<award-id>2014-1830</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>